Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
Galderma, the emerging pure-play dermatology category leader, today hosts the first edition of its Liquid Live event in Dubai as a chance to discuss with clinicians the future of innovation in the field of neuromodulation as well as showcasing the latest neuromodulators from its aesthetics portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231013777100/en/
Copyrights - Sylvain Granjon
To mark the progress in treatment optimization and showcase its commitment to further driving innovation, Galderma has organized the first ever Liquid Live event. This premium experience will convene over one hundred of Europe’s leading aesthetics practitioners to immerse themselves in the future of the neuromodulator field. The Liquid Live event will include presentations from renowned experts on key data, the latest market trends and changes in patient needs, and sharing insights to advance the future of neuromodulation in aesthetics together.
A year on from the launch of Alluzience®, the first and only liquid ready-to-use neuromodulator in Europe with rapid onset and effects lasting for up to six months, Galderma is now getting ready to launch the product in 13 new countries1. Indicated for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines, this launch opened a new era of innovation in neuromodulation. As a ready-to-use liquid formulation, it has the potential to improve safety and dosing accuracy compared to existing neuromodulators that require reconstitution, enabling more precision and higher patient satisfaction.
“Galderma is the leading innovator in neuromodulators and we are delighted to launch the Liquid Live event as an opportunity to convene leading experts in this field. Alluzience® has a unique profile and its launch in 13 new countries is another exciting step in our journey of driving differentiated innovation and expanding our portfolio.
Galderma is well-positioned to continue to build its category-leading pipeline in injectable aesthetics, with proven in-house R&D capabilities in medical aesthetics. This includes successfully developing RelabotulinumtoxinA internally as well as the world’s largest hyaluronic acid filler range, Restylane®. Along with Sculptra®, the first and original injectable poly-L-lactic acid collagen stimulator, Galderma’s offering in neuromodulators and fillers is the broadest, unparalleled injectable aesthetics portfolio.
Alluzience (abobotulinumtoxinA solution) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient. It should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment. Dosing and treatment intervals depend on assessment of the individual patient’s response. The treatment interval should be no more frequent than every three months. For more information, please see the Summary of Product Characteristics2.
Alluzience is a product under license from Ipsen. Alluzience is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience in the approved indication in Europe.
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane®, Dysport®, Azzalure®, Alluzience® and Sculptra® in Injectable Aesthetics; Soolantra®, Epiduo®, Differin®, Aklief®, Epsolay®, Twyneo®, Oracea®, Metvix®, Benzac® and Loceryl® in Therapeutic Dermatology; and Cetaphil® and Alastin Skincare® in Dermatological Skincare. For more information: www.galderma.com.
1 Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Romania, Slovenia and Slovakia
2 Alluzience Summary of Product Characteristics, 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
+41 76 315 26 50
Corporate Communications Director
+41 79 529 59 85
Head of Strategy, Investor Relations, and ESG
+41 21 642 78 12
Investor Relations and Strategy Director
+41 21 642 76 43
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capcom Reveals Dragon’s Dogma 2 Scheduled to Launch March 22, 2024!29.11.2023 02:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Dragon’s Dogma 2, the latest game in the Dragon’s Dogma series, is scheduled to be released on March 22, 2024. With the launch of Dragon’s Dogma 2, Capcom closes out a stellar year of major title releases for its 2023 fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128898951/en/ Dragon's Dogma 2 is a single player, narrative driven action-RPG and the latest title in the Dragon’s Dogma series. The game features intricately crafted, gorgeous visuals powered by Capcom’s proprietary RE ENGINE that elevate its unique gameplay experience to provide a truly immersive fantasy world sure to delight both newcomers as well as long-time fans of the series. (Graphic: Business Wire) Dragon’s Dogma 2 is the latest title in the series, and the first mainline entry since the original Dragon’s Dogma was released in 2012. The game is being developed on Capcom’s proprietary RE EN
Rocket Software to Acquire OpenText’s Application Modernization and Connectivity Business28.11.2023 22:20:00 CET | Press release
Rocket Software, Inc. (“Rocket Software”), a global technology leader driving modernization for the world’s largest companies, today announced it has signed a definitive agreement to acquire the Application Modernization and Connectivity business (AMC) of OpenText (NASDAQ: OTEX), (TSX: OTEX), which was formerly part of Micro Focus. The total purchase price is $2.275B. For decades, Rocket Software has been the partner solving complex IT challenges for the largest and most innovative organizations, across infrastructure, data, and applications. Rocket Software’s hybrid cloud strategy empowers customers to optimize their application portfolio wherever they are in their modernization journey, enabling them to bridge the gap to modern use cases without disrupting their mission-critical operations. This approach allows organizations to benefit from the mainframe's security and dependability while also taking advantage of powerful analytics tools in the cloud. AMC has been a leader in applica
NetApp and AWS Deliver a Nine Times Performance Increase for Amazon FSx for NetApp ONTAP28.11.2023 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, announced at re:Invent, scale-out FSx for ONTAP® file systems through its collaboration with AWS. Scale-out file systems offer up to nine times higher storage performance compared to existing file systems, enabling customers to run high-performance applications on AWS more quickly and efficiently. FSx for ONTAP enables customers to use ONTAP’s data management features for a wide variety of workloads, such as user and application file shares, relational databases (SAP HANA), data stores for VMware cloud on AWS and backup and disaster recovery. With the new enhancements, customers can now use FSx for ONTAP for a broader range of higher-performance use cases, such as high-performance computing (HPC), electronic design automation (EDA), visual effects (VFX) and film editing, life sciences, seismic analysis, machine learning, and generative AI. Organizations of all sizes are migrating on-premises workloads to AWS or deploy
Varberg Energi Selects Hansen to Power Intraday Trading28.11.2023 20:50:00 CET | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water and communications industries, is pleased to announce Varberg Energi, a Swedish energy company, as a new Hansen customer. Varberg Energi, which has recently added physical-trading operations and balance responsibility to its services, will leverage Hansen Trade to enable this. The intraday trading solution within Hansen Trade will allow Varberg Energi to automate intraday trading operations and balance management. With Hansen Trade as part of its everyday operating infrastructure, Varberg Energi will be able to take advantage of physical trading operations without the need to spend significant time and effort on manual operations. Jens Nordberg, Head of Energy Trading, Varberg Energi, commented: “We have recently made a strategic decision to insource physical-trading operations and balance responsibility. Combined with our flexibility portfolio, we believe that this will create the ri
Abu Dhabi’s Advanced Technology Research Council launches ‘AI71’: New AI Company Pioneering Decentralised Data Control for Companies & Countries28.11.2023 18:16:00 CET | Press release
In an era of rapid advancements across artificial intelligence (AI), Abu Dhabi’s Advanced Technology Research Council (ATRC) is making yet another bold stride with the launch of its new AI company, AI71. The entity builds on the Technology Innovation Institute’s (TII) Falcon generative AI models and will focus on multi-domain specializations while offering unprecedented AI data control options for companies and countries looking to self-host for greater privacy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128549220/en/ H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council launches AI71 along with H.E Faisal Al Bannai, Secretary General, Advanced Technology Research Council (Photo: AETOSWire) The new AI powerhouse was launched by H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Cou